Lupin Sales Rise 14% as Margins Narrow
Updated: 13 minutes ago
Katrela Ventures Daily Update · Investment, M&A and Business Innovation Digest · 4 November 2026
Key takeaways
Lupin's Q2 FY27 consolidated product sales rose 14% to ₹7,786 crore, while EBITDA fell 10.7% to ₹2,171 crore and the margin narrowed to 27.9% from 35.6%.
Profit after tax declined 22.2% to ₹1,155 crore; India sales grew 14.7% and other developed markets 45.7%, while emerging markets slipped 3.5%.
Fractal Analytics crossed $100 million in quarterly revenue for the first time; NLC India approved a ₹2,500 crore bond raise.
Funding: GIVA raised ₹975 crore and Peppermint Robotics ₹100 crore.
Stay ahead with the latest funding rounds, strategic acquisitions, and groundbreaking innovations shaping the business world!
📩 #Read the full update below.
01. TOP STORIES
NLC India Approves ₹2,500 Crore Bond Raise and New 660 MW Unit: The board of NLC India on 4 November approved raising up to ₹2,500 crore through privately placed, listed bonds in one or more tranches, along with an additional 660 MW unit at the Ghatampur plant of its arm Neyveli Uttar Pradesh Power. Standalone Q2 FY27 profit rose to ₹1,205 crore, helped by a deferred tax credit of ₹857.7 crore, and the board declared an interim dividend of ₹1.50 per share.
Fractal Analytics Crosses $100 Million in Quarterly Revenue: Fractal Analytics reported Q2 FY27 consolidated operating revenue of ₹956.5 crore, up 20% year on year (10% in constant currency), its first quarter above $100 million. Net profit rose 139% to ₹79.2 crore and the adjusted EBITDA margin improved 123 basis points to 16%.
02. QUICK TAKES
Lupin Sales Rise 14% as Margins Narrow
Ecosystem Scale: ₹7,786 Cr Sales Q2 FY27 | ₹2,171 Cr EBITDA Q2 FY27 | 27.9% EBITDA Margin Q2 FY27 | ₹1,155 Cr PAT Q2 FY27 | ₹3,020 Cr US Sales Q2 FY27 | ₹2,384 Cr India Sales Q2 FY27
Lupin reported its Q2 FY27 results on 4 November 2026, with consolidated product sales rising 14% to ₹7,786 crore and revenue from operations up 11.1% to ₹7,827 crore. EBITDA fell 10.7% to ₹2,171 crore, and the EBITDA margin narrowed to 27.9% from 35.6% a year earlier. Profit after tax declined 22.2% to ₹1,155 crore from ₹1,485 crore. The company did not attribute the decline to a single factor, though Managing Director Nilesh Gupta acknowledged "near-term challenges"; employee costs rose 28.8% to ₹1,424 crore and manufacturing and other expenses rose 23.2% to ₹2,438 crore.
The US remained Lupin's largest market at ₹3,020 crore, up 9.3% and 39% of sales, while India grew 14.7% to ₹2,384 crore. Other developed markets rose 45.7% to ₹1,182 crore and global API sales grew 20.2% to ₹308.6 crore, but emerging markets slipped 3.5% to ₹890.8 crore. R&D spend rose to ₹618.1 crore, or 7.9% of sales, from 7.6% a year earlier. Sequentially, profit fell 18.5% from ₹1,417 crore and the margin eased from 31.4%, as operating costs grew faster than the gross margin gain to 74.2%.
Globally, the IQVIA Institute (March 2026) projects medicine spending to grow at a 5–8% CAGR through 2030 to about $2.6 trillion, led by oncology, immunology, diabetes and obesity. It expects US net price growth to slow to 4–7% a year from 9.4% over the past five years, as nearly $200 billion of brand sales face patent expiry. In India, Pharmarack data (15 October 2026) shows the domestic market grew 13.5% in value and 2.9% in units in September 2026, with moving annual total value growth of 10.9%. Pharmarack said rising sales and units point to stronger demand and better acceptance of new launches, while IQVIA notes that India's medicine use is expanding faster than audits had captured, helped by government generic access programmes.
The tailwinds are largely domestic: Lupin's moving annual total growth of 13.7% in Pharmarack data runs ahead of the 10.9% market, and its other developed markets grew 45.7%. Peers also reported double-digit India growth this quarter, from 12% at Cipla to 17.3% at Sun Pharma. The headwinds sit in US generics, where Sun Pharma's US formulations fell 8.2% on lenalidomide erosion and Cipla's North America revenue declined 19%. Slower US net price growth and Lupin's faster-rising personnel and manufacturing costs add further pressure on margins.
Against listed peers on the same metrics, Lupin's revenue growth of 11.1% was just behind Sun Pharma (11.8%) and well ahead of Dr Reddy's (−1.5%) and Cipla (−2.4%). Its 27.9% EBITDA margin trailed Sun Pharma's 29.3% but stayed above Dr Reddy's 20.6% and Cipla's 18.7%. Lupin's 22.2% profit decline was smaller than Dr Reddy's 36% and Cipla's 35%, while Sun Pharma reported profit of ₹1,989 crore after exceptional charges without a year-on-year change in the source used. In the US, Lupin grew 9.3% against declines at Sun Pharma and Cipla; Dr Reddy's has not reported a comparable year-on-year US figure in that source.
Katrela's Take
➢Lupin's quarter shows Indian pharma earnings splitting between a firm domestic market and a tougher US generics cycle. For founders and MSMEs supplying APIs, intermediates and contract services, demand tied to India-focused portfolios looks steadier than US-linked volumes. The opportunity lies in chronic and specialty therapies at home and in other developed markets; the constraint is a cost base rising faster than sales. Metrics to track: EBITDA margin, US sales growth, India growth versus the market, and R&D as a share of sales.
Can India's domestic demand offset US generic price pressure for Indian drugmakers over the next few quarters?
03. FUNDING BRIEF
GIVA-Bengaluru-based fine jewellery brand-has raised ₹975 crore ($102.8 million approx.) in a funding round led by Multiples Alternate Asset Management, with participation from Epiq Capital and Edelweiss Discovery Fund.
Peppermint Robotics-Pune-based maker of autonomous cleaning robots-has raised ₹100 crore ($10.5 million approx.) in a Pre-Series B round led by pi Ventures and Crane Venture Partners, with participation from Asiana Fund.
Raising capital in healthcare, consumer or deeptech? Katrela Ventures helps founders plan the round and the numbers behind it.
Follow Aaditya Jain, Pradeep Jain and Katrela Ventures for expert insights on investment trends, M&A activities, and business strategy! 💡
Frequently asked questions
How did Lupin perform in Q2 FY27?
Consolidated product sales rose 14% to ₹7,786 crore and revenue from operations 11.1% to ₹7,827 crore, but EBITDA fell 10.7% to ₹2,171 crore, the EBITDA margin narrowed to 27.9% and profit after tax declined 22.2% to ₹1,155 crore.
Why are Indian pharma earnings diverging between India and the US?
Domestic demand is firm, with peers reporting double-digit India growth, while US generics face price erosion and slower net price growth, which weighs on US-linked revenue and margins.
What should pharma suppliers and founders track, according to Katrela Ventures?
EBITDA margin, US sales growth, India growth versus the market, and R&D as a share of sales. Demand tied to India-focused portfolios looks steadier than US-linked volumes.
This edition was first published in the Katrela Ventures Daily Update newsletter on LinkedIn. Subscribe to get the digest every morning.
Comments